

## RESEARCH ARTICLE

## Open Access



# Follow-up practices for high-grade extremity Osteosarcoma

Christian Rothermundt<sup>1\*</sup>, Beatrice M. Seddon<sup>2</sup>, Palma Dileo<sup>2</sup>, Sandra J. Strauss<sup>2</sup>, Joanne Coleman<sup>3</sup>, Timothy W. Briggs<sup>3</sup>, Sarah R. Haile<sup>4</sup> and Jeremy S. Whelan<sup>2</sup>

## Abstract

**Background:** The optimal conduct of follow-up (FU) of patients with osteosarcoma is uncertain. In the absence of any formal validation of optimal timing and method of surveillance, guidance is provided by oncology societies' recommendations. FU is designed to detect either local recurrence or metastatic disease at a time when early treatment is still possible and might be effective.

**Methods:** We performed a retrospective analysis of 101 patients with high-grade extremity osteosarcoma in a single centre. Chest x-ray (CXR) was used as routine surveillance method; however patients with initial lung metastases or previous suspicious findings had computed tomography (CT) scans.

**Results:** With a median FU time of 30.7 months 34 patients relapsed. Relapse-free survival after 5 years was 61 % (CI 52 %; 73 %), late relapses occurred in only two patients between 2 and 5 years of FU. Twenty-five of the 34 relapses were detected at routine FU appointments. All 8 local recurrences were noted clinically. Twenty-two patients had metastases confined to the lungs, either detected on CXR or CT. Thirty-two percent of patients with lung metastases only were salvaged successfully.

**Conclusions:** Routine FU in high-grade osteosarcoma results in clinical detection of local relapse, and detection of lung metastases by CXR at a time when metastatectomy is possible. The optimal time interval for FU appointments is not known, however we recommend more frequent surveillance visits during the two years after treatment. We hypothesize that routine CT scans are not required and propose CXR for detection of lung metastases.

**Keywords:** Osteosarcoma, Follow-up, Imaging

## Background

High-grade osteosarcoma is the most common primary bone tumour. It is a disease of childhood, adolescence and young adulthood [1]. Osteosarcoma survival rates for children and adolescents in Europe showed marked improvement up to the 1980s [2] and many osteosarcoma patients are cured by multi-agent chemotherapy and surgery [3]. However, a significant number of patients who are rendered free of disease by initial chemotherapy and surgery develop disease relapse. The opportunity to achieve a second complete remission by surgical resection is essential for survival [4].

FU time intervals, duration and investigations vary after treatment for high-grade extremity osteosarcoma [5, 6]. FU is designed to detect either local recurrence or metastatic disease at a time when early treatment is still possible and might be effective [7]. One prospective randomized trial on surveillance intensity in extremity sarcoma (soft tissue and bone) was recently reported [8]. Nevertheless, the optimal frequency of FU and the best radiologic method of lung surveillance continue to be unknown. Radiation exposure is a concern especially in young patients and should be balanced with the potential benefits of early detection of relapse [9, 10].

## Methods

This is a retrospective analysis of 101 consecutive patients with high-grade extremity osteosarcoma who presented to a single institution for treatment and/or FU

\* Correspondence: [christian.rothermundt@kssg.ch](mailto:christian.rothermundt@kssg.ch)

<sup>1</sup>Division of Oncology/Haematology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland

Full list of author information is available at the end of the article

from 2003 to 2009. Routine FU consisted of clinical examination, CXR and plain films of primary site 2-monthly year 1, 3-monthly year 2 and 3, and 6-monthly year 4 and 5. Confirmatory CT scans were performed in all patients with suspicious findings. Routine CT scans were performed at the end of treatment, when suspicious finding had been observed previously and in a patient with resected lung metastases. Patients were routinely seen and assessed by the treating oncologist or the surgeon. Patient and tumour data were collected from hospital records. Data collection was in accordance with local ethical standards [11]. Survival rates were computed using the method of Kaplan and Meier [12, 13]. As 50 % survival was not reached, 1, 2, and 5 year survival rates with 95 % confidence intervals are presented. Event rates by site of relapse were examined using cumulative incidence functions for survival data with competing risks [14]. No hypothesis testing has been performed. All analysis was performed in the R programming language (version 3.2.2) [15].

## Results

Median age at surgery was 18.7 years (range (4.7, 66.3)). The primary tumour was located in the lower extremity in 87 patients, and in the upper extremity in 14 patients. Ninety-three patients had localized disease, 5 patients had lung metastases at diagnosis, 2 patients a single bone and 1 patient a lymph node metastasis. All patients underwent surgery, 100 patients received chemotherapy, 92 pre- and postoperatively. Standard chemotherapy consisted of high-dose methotrexate, doxorubicin and cisplatin (MAP) [16]. Eight patients had radiotherapy. With a median FU time of 30.7 months (range (2.2 months, 101.6 months)), 34 patients relapsed.

Five of the 8 patients with initial metastases (60 %), and 29 patients with initially localised disease relapsed (31 %). Of 34 patients with a relapse, 15 died (44 %). Overall survival (OS) estimates for all patients at 1, 2, and 5 years are 98, 94 and 73 %, respectively (Fig. 1).

Survival from time of relapse estimates at 1, 2, and 5 years are 88, 60 and 29 %, respectively (Fig. 2).

Twenty-five of the 34 relapses were detected at routine FU appointments. All 8 local recurrences were noted clinically, seven by the patients and one by the physician. Signs or symptoms of local recurrence were masses or swelling in 7 patients and pain in 1 patient, respectively. Half of the local relapses were detected or reported at routine FU, the other half outside scheduled appointments. The four patients with local relapse only were treated with curative intent and three patients were salvaged. However, three of the four patients with local relapse and synchronous metastases died, one patient was alive but not cured.

Twenty-two patients had metastases confined to the lungs (Table 1). Three patients were symptomatic at relapse with a pleural effusion, cough, and a pulmonary embolism. In 10 patients routine CXR revealed pulmonary metastases. In 9 patients lung metastases were detected on planned CT: 4 on end of treatment scans, 3 with suspicious findings during or at end of treatment, 1 had lung metastases resected and was followed by CT, in one patient the indication for a CT scan is unclear.

Nine of the 10 patients with CXR-detected lung metastases were treated with curative intent by surgery only ( $n = 4$ ) or surgery and chemotherapy ( $n = 5$ ) and 5 remain relapse-free. Among the 9 patients with CT detected lung metastases 6 were treated with curative intent and 2 remain relapse-free. In summary, 32 % of patients with lung metastases only were salvaged successfully. The higher rate of salvaged patients after CXR-detected compared to CT-detected lung metastases is probably attributable to the fact that the baseline risk of relapse was higher in the patient group followed with chest CT scans.

Most relapses occurred within the first two years after end-of treatment and only two patients experienced a relapse between years 2 to 5. Relapse-free survival estimates at 1, 2, and 5 years are 83, 64 and 61 %, respectively (Fig. 3).


In 101 patients, there were a total of 1'004 appointments without detection of relapse, corresponding with costs of Great Britain Pound (GBP) 151'604 (outpatient appointment (OPA) at University College London Hospitals (UCH) + CXR + plain films of primary site) to GBP 287'144 (OPA at UCH + CT + plain films of primary site). Median number of visits without relapse detected was 8 (0–21), with costs of either GBP 1'210 (0 – 3'170) or 2'290 (0 – 6'010). It is notable that none of the relapses were detected after 26 months, even after a potential FU to 91 months.

## Discussion


In this small retrospective analysis of 101 patients with high-grade extremity osteosarcoma the median time to relapse and the sites of relapse are similar to larger series [3]. It confirms that the lungs are the main site of metastases from osteosarcoma [17]. Nineteen of the 34

**Table 1** Sites of relapse


Site	n	% of relapses
Local	4	12
Local and lung	3	9
Local and bone	1	3
Lung	22	65
Lung and bone	3	9
Bone	1	3



**Fig. 1** Overall survival



**Fig. 2** Overall survival after relapse



**Fig. 3** Cumulative incidence of relapse

patients (56 %) who experienced relapse were still alive in our analysis after a median FU time of 30.7 months (range (2.2 months, 101.6 months)); however FU was much shorter compared to a previously reported series of 110 relapsed osteosarcoma patients and a survival rate of 16.4 % [4] after a median FU of 13.7 years (range (4.6 years, 33.5 years)). In another retrospective analysis the projected 5-year post relapse survival (PRS) rate was 28 %. Patients who had complete surgery of recurrence had a 5-year PRS of 39 %, whereas for those who did not have complete surgery, PRS was 0 % at 3 years [18]. The importance of complete resection was also demonstrated in two other retrospective reviews [19, 20]. Combination chemotherapy may contribute to a modest improvement in outcome for relapsed patients [3].

One limitation of this retrospective analysis is that we cannot present data on histological response to preoperative chemotherapy, which is an independent prognostic parameter for relapse and survival [21]. In European and American Osteosarcoma Study Group (EURAMOS)-1 50 % of osteosarcoma patients obtained a good response to preoperative MAP chemotherapy, and 50 % had a poor response [22]. After a median FU of 44 months 174 events were reported in 716 patients with good histological response [23], whereas 300 events were reported in 618 patients with a poor histological response after a median FU of 54 months, respectively [24]. Due to the differences in

frequency of events, FU might ideally be adjusted to the risk of relapse according to histological response.

We do not report on results of blood tests, which are routinely performed during FU. We think blood tests are unhelpful in detecting relapses. However, blood tests might be useful to detect late organ toxicity following intensive chemotherapy.

The only randomised trial of FU strategies in sarcoma patients [8] compared chest imaging modalities (CXR and CT scans) and frequency of FU (3-monthly and 6-monthly visits) in 359 bone and 151 soft tissue extremity sarcomas. CXR was non-inferior as compared with CT scans (3-year OS 67 and 66 %, respectively; disease-free survival 54 and 49 %, respectively). However the trial could not conclusively demonstrate non-inferiority for less frequent FU visits.

Most relapses in our series occurred within the first two years after end-of treatment and when patients are seen every two to three months, we therefore doubt that more frequent visits and scans would have altered the course of disease. However, we cannot exclude this nor that in the two patients, who experienced a relapse between years 2 to 5, earlier detection of relapse would have made treatment easier and more successful.

The question remains whether early relapse is a sign of more aggressive disease and early detection can substantially change the course of the disease and outcome.

We previously reported data from a retrospective analysis of patients with extremity soft tissue sarcoma and showed that routine CXR in FU can detect lung metastases suitable for surgical resection. Local relapse of soft tissue sarcoma is almost always detected by patients or physicians, and routine scanning of the primary site is of doubtful benefit [25]. In line with this data, we now report a clinical detection rate of 100 % (8/8) for local relapse in high-grade extremity osteosarcoma. X-rays of the primary tumour site during surveillance of osteosarcoma may be useful to inform on reconstructive results and prosthesis function [26, 27], but are of little relevance for detection of local relapse.

CXR detected pulmonary metastases in 10/22 patients, 9 patients underwent complete resection of lung metastases, 5 of whom were relapse-free at last FU (2 after surgery and 3 after surgery and chemotherapy). Patients with CT detected pulmonary metastases were either assessed at end of treatment ( $n = 4$ ), due to suspicious findings during or at end of treatment ( $n = 3$ ), or after lung metastases resection ( $n = 1$ ). In one patient the reason for a CT scan remains unclear. Among patients with CT detected pulmonary metastases 2 remain relapse-free at last FU. We postulate that CXR is sufficient for routine scanning of the lungs, however we would advocate CT scans in patients with suspicious findings on CXR or previous abnormalities, which require following.

## Conclusion

Routine FU with clinical examination by patient and physician supplemented by CXR in high-grade extremity osteosarcoma results in clinical detection of local relapse, and detection of lung metastases at a time when metastatectomy is possible. The optimal time interval for FU appointments is not known. The higher relapse-rate during the first two years of FU suggest more frequent examination, however this has not been shown to have impact on outcome. We hypothesize that 2- or 3-monthly FU during the first 2 years after curative treatment for high-grade extremity osteosarcoma with CXR is feasible and may be sufficient in patients who had no previous abnormalities and remain asymptomatic.

## Ethics approval and consent to participate

No individual consent has been obtained from patients. Only anonymized data from the University College London Hospital database was used. This analysis is formally counted as service evaluation. Therefore, no formal ethics committee approval is necessary according to local standards [11].

## Consent for publication

Not applicable.

## Availability of data and materials

The dataset supporting the conclusions of this article is included within the article and its Additional file 1.

## Additional file

**Additional file 1:** Bone Sarcoma Data Set. (CSV 6 kb)

## Abbreviations

CT: computed tomography; CXR: chest x-ray; EURAMOS: European and American Osteosarcoma Study Group; FU: follow-up; GBP: Great Britain pound; MAP: high-dose methotrexate, doxorubicin and cisplatin; OPA: outpatient appointment; OS: overall survival; PRS: post relapse survival; UCH: University College London Hospitals.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

CR participated in the design of the study, conceived of the study, participated in its design and coordination, interpreted the results and wrote the manuscript. BMS participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. PD participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. SJS participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. JC participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. TWB participated in the design of the study, conceived of the study, and participated in its design and coordination and helped to draft the manuscript. SRH performed the statistical analysis. JSW participated in the design of the study, conceived of the study, and participated in its design and coordination, interpreted the results and helped to draft the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

None.

## Funding

This work did not receive funding.

## Author details

<sup>1</sup>Division of Oncology/Haematology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland. <sup>2</sup>London Sarcoma Service, University College London Hospitals, London NW1 2BU, UK. <sup>3</sup>Department of Orthopaedic Surgery, Royal National Orthopaedic Hospital, Middlesex HA7 4LP, UK. <sup>4</sup>Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland.

Received: 8 April 2015 Accepted: 3 May 2016

Published online: 06 May 2016

## References

1. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirilaque MD, Casali PG. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. *Eur J Cancer (Oxford, England : 1990)*. 2013;49(3):684–95.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer*. 2009;115(7):1531–43.
3. Kempf-Bielack B, Bielack SS, Jurgens H, Branschoid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). *J Clin Oncol*. 2005;23(3):559–68.
4. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. *Cancer*. 2013;119(14):2645–53.

5. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 Suppl 3:iii113-123.
6. NCCN Clinical Practice Guidelines in Oncology. [https://www.nccn.org/professional/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professional/physician_gls/pdf/bone.pdf).
7. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2012;23 Suppl 7:vii100-9.
8. Puri A, Gulia A, Hawaldar R, Ranganathan P, Badwe RA. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. *Clin Orthop Relat Res.* 2014;472(5):1568-75.
9. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med.* 2007;357(22):2277-84.
10. Mettler Jr FA, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. *Radiology.* 2008;248(1):254-63.
11. Authority HR. Defining research - National Research Ethics Service guidance to help you decide if your project requires review by a Research Ethics Committee. In.; rev. April 2013. <http://www.hra-decisiontools.org.uk>
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc.* 1958;53(282):457-81.
13. Therneau TM. A package for survival analysis in S, R package version 2.37-7. 2014.
14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med.* 1999;18(6):695-706.
15. CORE TEAM R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
16. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol.* 2005;23(9):2004-11.
17. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoan A, Holmes EC, Eilber FR, Eckardt JJ. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. *J Clin Oncol.* 1994;12(9):1849-58.
18. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Prever AB, Fagioli F, Comandone A, Bacci G. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. *J Clin Oncol.* 2003; 21(4):710-5.
19. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. *Cancer.* 2005;104(10):2214-21.
20. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, Versari M, Picci P. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. *Acta oncologica (Stockholm, Sweden).* 2005;44(7):748-55.
21. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol.* 2002;20(3):776-90.
22. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Bohling T. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. *Ann Oncol.* 2015;26(2):407-14.
23. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Papai Z, Meyer J. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. *J Clin Oncol.* 2015;33(20):2279-87.
24. Marina S, Smeland S, Bielack S, Bernstein M, Jovic G, Hook JM, Krailo M, Butterfass-Bahloul T, Kühne T, Eriksson M. MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1 CTOS 2014, Paper 032. 2014.
25. Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. *Br J Cancer.* 2014; 110(10):2420-6.
26. Blunn GW, Briggs TW, Cannon SR, Walker PS, Unwin PS, Culligan S, Cobb JP. Cementless fixation for primary segmental bone tumor endoprostheses. *Clin Orthop Relat Res.* 2000;372:223-30.
27. Yasko AW. Surgical management of primary osteosarcoma. *Cancer Treat Res.* 2009;152:125-45.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

